Navigation Links
National award honors CHOP scientist for career work in gene therapy for hemophilia

Katherine A. High, M.D., of The Children's Hospital of Philadelphia (CHOP) was honored for her trailblazing scientific and clinical research in the bleeding disorder hemophilia when she received the 2013 E. Donnall Thomas Prize from the American Society of Hematology (ASH) at its annual meeting on Dec. 9 in New Orleans.

Named for the late Nobel Prize laureate E. Donnall Thomas, the award recognizes pioneering research achievements in hematology that have helped move the field forward. An internationally recognized expert in the molecular basis of hemophilia, Dr. High has developed novel approaches to correcting hemophilia with gene therapy in studies over the past two decades. Her studies continue today in a current NIH-funded clinical trial for hemophilia.

The Prize recipient customarily delivers the E. Donnall Thomas Lecture to the ASH conference audience. Dr. High's lecture, "Sailing to Ithaca: Gene Therapy's Odyssey from Investigational Agent to Therapeutic Product," described the successes and obstacles of the evolving science and practice of gene therapy as it pursues the goal of offering long-lasting treatments of previously incurable diseases.

In presenting the E. Donnall Thomas Prize, ASH president Janis L. Abkowitz, M.D., said, "Dr. High is unquestionably a leader in gene therapy and has made remarkable, groundbreaking contributions to the field, demonstrating creativity, determination, and the ability to overcome numerous obstacles. Through her countless discoveries, Dr. High has transformed the notion of utilizing genetically engineered mechanisms for treatment of incurable inherited disorders from a distant vision to reality."

Dr. High is the founder and director of the Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia. She also is a Howard Hughes Medical Institute Investigator, the William H. Bennett Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, and an attending physician at CHOP. A former president of the American Society of Gene and Cell Therapy, she also is an elected member of both the Institute of Medicine and the American Academy of Arts and Sciences. She is a scientific co-founder and advisor to Spark Therapeutics, a fully integrated gene therapy company launched in October 2013 with a capital investment from CHOP.


Contact: John Ascenzi
Children's Hospital of Philadelphia

Related biology news :

1. Researchers named to National Academy of Inventors
2. Kurt H. Becker Named a Fellow of the National Academy of Inventors
3. University of Tennessee vice chancellor named National Academy of Inventors Fellow
4. First International Bioenergy Conference brings together world-leading experts
5. International gene therapy trial for bubble boy disease shows promising early results
6. OU professor receives national fellowship to complete biography on Ancel Keys and the American diet
7. 20th International AIDS Conference (AIDS 2014) plenary speakers announced
8. National survey finds frog abnormalities are rare
9. China National Genebank initiates collaboration to sequence transcriptomes of 1,000 fish species
10. Women & Infants earns $3 million grant from National Institutes of Health
11. Antibiotic resistance is a international issue that better education can address
Post Your Comments:
Related Image:
National award honors CHOP scientist for career work in gene therapy for hemophilia
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: